MONTE ROSA THERAPEUTICS ($GLUE) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.45 per share, missing estimates of -$0.39 by $0.06. The company also reported revenue of $4,210,000, missing estimates of $11,100,996 by $-6,890,996.
You can see Quiver Quantitative's $GLUE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MONTE ROSA THERAPEUTICS Insider Trading Activity
MONTE ROSA THERAPEUTICS insiders have traded $GLUE stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $GLUE stock by insiders over the last 6 months:
- MARKUS WARMUTH (President & CEO) has made 0 purchases and 6 sales selling 24,399 shares for an estimated $470,918.
- EDMUND DUNN (Principal Accounting Officer) has made 0 purchases and 3 sales selling 25,839 shares for an estimated $467,382.
- FILIP JANKU (Chief Medical Officer) sold 9,189 shares for an estimated $179,160
- PHILIP NICKSON (Chief Business & Legal Officer) sold 5,845 shares for an estimated $103,412
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
MONTE ROSA THERAPEUTICS Hedge Fund Activity
We have seen 103 institutional investors add shares of MONTE ROSA THERAPEUTICS stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC added 4,622,151 shares (+inf%) to their portfolio in Q4 2025, for an estimated $72,475,327
- BVF INC/IL removed 1,824,246 shares (-32.2%) from their portfolio in Q4 2025, for an estimated $28,604,177
- FMR LLC removed 1,512,155 shares (-53.8%) from their portfolio in Q4 2025, for an estimated $23,710,590
- STATE STREET CORP added 1,260,707 shares (+148.9%) to their portfolio in Q4 2025, for an estimated $19,767,885
- VERSANT VENTURE MANAGEMENT, LLC removed 1,201,907 shares (-27.4%) from their portfolio in Q1 2026, for an estimated $19,771,370
- MPM BIOIMPACT LLC added 1,173,376 shares (+inf%) to their portfolio in Q4 2025, for an estimated $18,398,535
- BRAIDWELL LP added 948,316 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,869,594
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
MONTE ROSA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $GLUE recently. We have seen 3 analysts offer price targets for $GLUE in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Michael Schmidt from Guggenheim set a target price of $30.0 on 03/18/2026
- Derek Archila from Wells Fargo set a target price of $29.0 on 03/18/2026
- Edward Tenthoff from Piper Sandler set a target price of $37.0 on 01/14/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
